ClinicalTrials.gov
ClinicalTrials.gov Menu

Breast Cancer With Over-expression of erbB2-BRAINSTORM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01064349
Recruitment Status : Completed
First Posted : February 8, 2010
Last Update Posted : September 14, 2018
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression.

Condition or disease Intervention/treatment
Cancer Drug: Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer

Study Type : Observational
Actual Enrollment : 144 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)
Study Start Date : May 6, 2009
Actual Primary Completion Date : June 3, 2011
Actual Study Completion Date : June 3, 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Group/Cohort Intervention/treatment
Breast cancer patients with brain metastases
Female Erb2+ breast cancer patients with brain metastases diagnosed between January 2006 and December 2008 in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).
Drug: Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
Trastuzumab or Lapatinib




Primary Outcome Measures :
  1. To describe the treatment pattern of brain metastasis in ErbB2 over-expressing breast cancer in Asia Pacific countries. [ Time Frame: Time (in months) from date of first diagnosis of brain metastasis through to death or end of study period ]

Secondary Outcome Measures :
  1. To describe the survival of ErbB2 over-expressing breast cancer patients with brain metastasis after diagnosis of brain metastasis in relation to the receipt of anti-erbB2 therapy. [ Time Frame: Time (in months) from date of first diagnosis of brain metastasis through to death or end of study period ]
  2. Describe association between usage of anti-erbB2 therapy (before brain metastasis) & 1) time interval from diagnosis of erbB2+ breast cancer to occurrence of brain metastasis and 2) occurrence of brain metastasis as the first site of disease progression [ Time Frame: Time (in month) between the date of diagnosis of erbB2+ breast cancer and date of first diagnosis of brain metastasis ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
This study aims to enrol approximately 300 Erb2+ breast cancer cases with brain metastases in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).
Criteria

Inclusion Criteria:

  1. Female patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as determined by respective institutional standards, and will be based on medical history only.
  2. Brain metastasis diagnosis made between January 2006 - December 2008.

Exclusion Criteria:

  1. Women who have another primary cancer diagnosed between the time of breast cancer diagnosis and brain metastasis..
  2. Patient has leptomeningeal metastases only without parenchymal brain involvement (since this pattern of the disease requires a different treatment approach.)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01064349


Locations
Philippines
GSK Investigational Site
Pasay City, Philippines, 1300
GSK Investigational Site
Quezon City, Philippines, 1101
GSK Investigational Site
Quezon City, Philippines, 1102
Singapore
GSK Investigational Site
Singapore, Singapore, 119074
Thailand
GSK Investigational Site
Bangkok, Thailand, 10110
GSK Investigational Site
Bangkok, Thailand, 10310
GSK Investigational Site
Bangkok, Thailand, 10330
GSK Investigational Site
Bangkok, Thailand, 10400
GSK Investigational Site
Bangkok, Thailand, 10700
GSK Investigational Site
Chiangmai, Thailand, 50200
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Publications:
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01064349     History of Changes
Other Study ID Numbers: 113349
First Posted: February 8, 2010    Key Record Dates
Last Update Posted: September 14, 2018
Last Verified: May 2018

Keywords provided by GlaxoSmithKline:
ErbB2+ breast cancer
ErbB2 treatment
brain metastases

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases